ABIVAX (Euronext Paris: ABVX), to Clinical-Stage Biotechnology Company, have summarized Trading of its Ordinary Shares On Euronext Paris As of July 24, 2025, at 3:30 pm Cest.
The Trading Halt, Which Began at 9:00 am Cest, was initiated to facilitate the Allocation and Pricing of Abivax’s Recently Announced American Depositary Shares (ADS) Offering in the United States.
Key Details for Investors
- Trading Halt Rationale: The Temporary Trading Allowed Abivax to Manage Investor Allocations and Disclose The Pricing for its New Ads Public Offering in the Us Each Ads is equivalent to One Ordinary Share, With Nominal Value of € 0.01. This structure is designated to enhance The Company’s Capital Access and Broaden ITS Investor on An International Scale.
- Potential Shareholder Impact: Investors Should Note The Possibility of Dilution Due to The Issuance of New Shares Through the Ads Offering. The expansion aims to support abivax’s ongoing growth and the advancement of its therapeutic pipeline, but it may impact the value of existing share in the near term.
- Company Focus: ABIVAX SPECIALIZES INVELOPING TREATMENTS THAT Use the Body’s Natural Regulatory Mechanisms to Modulate The Immune Response In Chronic Inflammatory Diseases. ITS Lead candidate, obefazimod (ABX464), is in phase 3 clinical trials targeting moderately to severely active ulcerative colitis.
- Market Context: The return to trading comes at a pivotal Moment, coinciding with heightened investor focus on biotech innovation and clinical-stage advances. The Capital Raised Through the ads offering is intended to accelerate the Development of Abivax’s Main Therapeutic Programs, Reinforcing its Position in the Global Biotechnology Sector.
What’s Next?
Investors Should Monitor Abivax’s Continued Updates On The Progress of Its Public Offering, Allocation Details, and The Development Milestones of ITS Lead Drug Candidates.
As The Company Navigates This Critical Phase, Market Participants Are Advised To Considers the Growth Potential and The Risks Associated With Share Dilution in Their Assessment of Abivax’s Invest Outlook.
